USA flag logo/image

An Official Website of the United States Government

AZA BICYCLO NONANE SEROTONIN TRANSPORTER RADIOTRACERS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71741
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
MH071022
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Molecular Neuroimaging, L.l.c.
60 TEMPLE STREET, SUITE 8A NEW HAVEN, CT -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: AZA BICYCLO NONANE SEROTONIN TRANSPORTER RADIOTRACERS
Agency: HHS
Contract: 1R43MH071022-01
Award Amount: $499,990.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this research project is to define the structure and radioactive label for ligands that will permit quantitative measurement of serotonin transporter (5-HTT) sites in living brain by external imaging with positron or single-photon emission tomography (PET or SPECT). The serotonin transporter is known to play a role in several physiological and pathophysiological processes, especially in depression, anxiety, and psychosis, as demonstrated by post-mortem and preliminary imaging studies. A radiotracer that bound specifically to 5-HTT would be of great utility in diagnosis, monitoring treatment, and research of such disorders. However, there is not yet a suitable tracer that allows quantitation in areas of the brain with low densities of 5-HTT, such as the cortex. In this application we propose to test the hypothesis that a novel structure, aza-bicyclo-[3.2.2]-nonane, will have the right combination of transporter binding affinity and pharmacological specificity to allow us to detect the serotonin transporter in the region of low density. In preliminary experiments using a classical structure-activity relationship (SAR) approach, we found that certain aza-bicyclo-[3.2.2]-nonane ethers showed nanomolar affinity to 5-HTT. We will extend this SAR to a larger library using parallel synthesis and purification. The ligand candidates will be screened for pharmacological affinity and specificity to 5-HTT versus competing binding sites. The most promising candidates will be radiolabeled with radionuclides, F-18, or 1-123 as appropriate to the molecule, and evaluated by imaging in vivo in non-human primates in a dedicated PET or SPECT imaging device.

Principal Investigator:

Gilles D. Tamagnan

Business Contact:


2034014351
Small Business Information at Submission:

MOLECULAR NEUROIMAGING, LLC
MOLECULAR NEUROIMAGING, LLC 60 TEMPLE ST, STE 8A NEW HAVEN, CT 06510

EIN/Tax ID: 061594851
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No